Study Finds No Differences in Oral Health Quality of Life in Children With Hemophilia
Despite having lower oral health scores, children with hemophilia showed no differences in oral health-related quality of life compared to children…
Articles by Joana Carvalho, PhD
ISTH-BAT Is Useful to Identify, Assess Hemophilia Patients, Study Suggests
The International Society on Thrombosis and Hemostasis (ISTH) created a Bleeding Assessment Tool (BAT) that is useful to identify and assess disease…
Novoeight Safe, Effective in Hemophilia A Patients Over Long Term, Phase 3b Trial Shows
Long-term treatment with Novoeight (turoctocog alfa) is safe and effective at preventing bleeding episodes in patients with…
Catalyst Announces Updates on Two Lead Compounds for Hemophilia
Catalyst Biosciences recently announced updates on two of its lead compounds — Factor VIIa (FVIIa) marzeptacog alfa (activated) (MarzAA) and Factor IX (FIX) dalcinonacog…
Preventive Use of Idelvion Lets Kids with Hemophilia B Need Fewer Infusions, Trial Shows
Prophylaxis with Idelvion (rIX‐FP) significantly improved clinical outcomes and quality of life for children with hemophilia B…
Bayer Announces the Approval of Jivi for Hemophilia A in Europe
Jivi (BAY94-9027), a lab-made version of the blood clotting factor VIII (FVIII), has been approved by the…
Bioverativ to Present New Data on Hemophilia and Other Blood Disorders at ASH
Bioverativ will present some of its most recent therapeutic advancements regarding hemophilia and other blood diseases at the 60th Annual…
Hemlibra Reduces Bleeds in Hemophilia A Patients Without Inhibitors, Phase 3 Trial Shows
Hemlibra (emicizumab) was able to prevent excessive bleeding in patients with severe hemophilia A without inhibitors, according to results…